Data presented support broad potential therapeutic applications of MRT-6160 in a variety of autoimmune and inflammatory disorders driven by underlying dysregulation of T- and B-cells, including rheumatoid
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling around 50 points on Tuesday.
The Dow traded down 0.09% to 33,954.39 while the NASDAQ fell 0.37% to 13,517.59. The S&P 500 also fell, dropping, 0.10% to 4,369.41.
Gainers
SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining around 100 points on Tuesday.
The Dow traded up 0.31% to 34,090.15 while the NASDAQ fell 0.05% to 13,560.52. The S&P 500 also rose, gaining, 0.25% to 4,384.43.